Table 2.
Univariate analysis of the patient cohort.
| Variable | Response | No response | p value |
|---|---|---|---|
| HRS type 1/2, N | 47/18 | 45/9 | 0.165 |
| Ascites, grade 1/2/3 | 9/38/18 | 11/25/16 | 0.466 |
| Treatment, median days (IRQ) | 9 [6–14] | 10.5 [5–19] | 0.350 |
| HE, grade 1/2/3 | 46/15/3 | 39/14/1 | 0.699 |
| Serum protein, g/L | 5.84 ± 1.27 | 5.30 ± 1.47 | 0.040 |
| INR | 1.60 ± 0.52 | 1.64 ± 0.44 | 0.698 |
| Serum sodium (mmol/L) | 133.60 ± 6.21 | 133.12 ± 5.73 | 0.714 |
| Serum potassium (mmol/L) | 4.34 ± 0.80 | 4.22 ± 0.71 | 0.381 |
| Serum creatinine (mg/dL) | 2.79 ± 1.24 | 3.07 ± 1.47 | 0.207 |
| Urea (mg/dL) | 55.30 ± 24.68 | 67.47 ± 51.59 | 0.189 |
| Bilirubin (mg/dL) | 8.12 ± 10.23 | 10.59 ± 12.29 | 0.901 |
| Terlipressin dose (mg) | 26.43 ± 30.86 | 32.11 ± 31.57 | 0.450 |
| Albumin dose (g) | 266.26 ± 236.31 | 298.14 ± 252.02 | 0.612 |
HE: hepatic encephalopathy; INR: international normalized ratio.